MedTrace Logo

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2026-04-28

No results posted yet for this study

Summary

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

Conditions

  • Treatment-resistant Depression (TRD)

Interventions

DRUG

ALTO-207

ALTO-207 BID

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

  • Alto Neuroscience

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-11-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07553637 on ClinicalTrials.gov